{"name":"Akari Therapeutics","slug":"akari","ticker":"AKTX","exchange":"NASDAQ","domain":"akaritx.com","description":"Akari Therapeutics is a biopharmaceutical company focused on rare diseases and immunology. The company's top drugs include Coversin, a complement inhibitor, and Nomacopan, a multi-targeted inhibitor of the complement and leukotriene pathways. Akari Therapeutics is positioned to address significant unmet needs in the treatment of rare and severe diseases. Its pipeline is focused on developing innovative therapies for patients with limited treatment options.","hq":"London, UK","founded":0,"employees":"","ceo":"Clive Richardson","sector":"Rare Disease / Immunology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$18M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":6983000,"netIncome":-19791000,"cash":50562000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"Coversin patent cliff ($0.0B at risk)","drug":"Coversin","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Nomacopan patent cliff ($0.0B at risk)","drug":"Nomacopan","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Coversin","genericName":"Coversin","slug":"coversin","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Coversin","genericName":"Coversin","slug":"coversin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Akari Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Akari Therapeutics reported its financial results for the fourth quarter and full year 2023, highlighting its progress in developing its pipeline of rare disease therapies.","drugName":"","sentiment":"neutral"},{"date":"2023-11-29","type":"deal","headline":"Akari Therapeutics Announces Collaboration with the University of California, San Francisco (UCSF)","summary":"Akari Therapeutics announced a collaboration with the University of California, San Francisco (UCSF) to develop new treatments for rare diseases.","drugName":"","sentiment":"positive"},{"date":"2023-09-18","type":"trial","headline":"Akari Therapeutics Announces Positive Topline Results from Phase 2 Clinical Trial of Nomacopan in Recurrent and/or Refractory Bullous Pemphigoid","summary":"Akari Therapeutics announced positive topline results from its Phase 2 clinical trial of Nomacopan in recurrent and/or refractory bullous pemphigoid.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNWUZoeXlQSFR1anktZ1lYdTFRb3JpVHQ1YkJfOE9FSkRBeVRHNDYybHJUWVpRbmduVUI5WElIM3ZoNWpqWTQwb3E3QnZVSzRiNzRYRUw2TjF3OFRwc2tTbGcwajZiUlFNVjJnUHBFUUMtOFdIOVUwNmdUckU1NU85Qmg0R2VrazJMaGtOUmFtLS12MHg5VXlhTGxVSEpqREtXMG0xQzJBZVJfRjM3QW9oUm1tUkVyZzgtQlNfSVJNZHhhcVphTnlEWHpXQ1RKbU0?oc=5","date":"2026-04-06","type":"deal","source":"Contract Pharma","summary":"Akari Therapeutics Partners with WuXi XDC to Accelerate Development of Novel PH1 Payload - Contract Pharma","headline":"Akari Therapeutics Partners with WuXi XDC to Accelerate Development of Novel PH1 Payload","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNTXZBZmRERGlQWVBSTmU5LUZnSkRIUW5hZURjZnBrYjlvS2g2dmxIRnpxZjVSY2lMRlVka2k3Q2pLdW1FblllNDhsRWlfbVBLVHBHNnNkYkE3Z2pzQlNDT2NWMkZlX2NZVU1lbk1IdTVhSWk5MFBqamhIUEtxaUtLcl95YnBGTG9WUjZhaUVTUGhfMm5BMlZGQ1JhSFFDZ0FabUF4Tk9BWWhjd3NXU0pBUDFCZi0?oc=5","date":"2026-03-19","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga","headline":"12 Health Care Stocks Moving In Thursday's Intraday Session","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQUUpIV2R5V1ZENDVJS08yMDJZNVNuaUF2TnpVaUt3bUdkLW1VTDlwUDdRbDlxdG0waFk0Yk0zdDIyaHl4RGxTdklkYmotWS1TV0duRnBuTUp0Z2ZkZUJzMnNrMHVYQ0FoaW85M1l6SGZOc2dlX3cwZnExWHNqbk1nM015anVmOFVvR0dUUnZaZWlrVzNkWGtuczJRcVBNRWdadVg5NVRhbUpORlFrTFZ0WjBSM2lNNWtEam9IRDJ0bDJsbXA3SjdOTDQwYw?oc=5","date":"2026-03-04","type":"pipeline","source":"Stock Titan","summary":"Akari Therapeutics (NASDAQ: AKTX) holder reports 8.9% ownership - Stock Titan","headline":"Akari Therapeutics (NASDAQ: AKTX) holder reports 8.9% ownership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPdkNSODZHN2JaSFRrMHpRUGdXYW8wM3pFaW9hLXVSSS10VlR3YlBOS3RXand0ajNzZG1xSjlwMTJwdU9JcGxLMkpZcExCZ0JPNUk3cGV0UEh6bGpBUTE1My00aHRsYV9YanBjT0V2QXlPU2tlQ2k0SjNzX2pIazdFVTFqdjlzNnNBcGdVRnBvaHlUTjZnelVCMHY5S1BCU3QxeC02MmdFeXJLOW1FbF8yV01IdHktUQ?oc=5","date":"2026-03-03","type":"pipeline","source":"Seeking Alpha","summary":"Most and least shorted healthcare stocks with up to $2B market cap in February - Seeking Alpha","headline":"Most and least shorted healthcare stocks with up to $2B market cap in February","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNTF9Zd0x3LWhIU2o2VlYyazFWdkFHT0pFRGo1VDlXUlJ0bkdrdjJFLUhuUEZYNjJyQnRMQ2I2Qkl6M21XdnFyTmVGTWJJVDVBcko1STRYOXZubG5QSDQtb2ZWbVpRVUJkNzM2R04yYnZzZ1ByNzFYalB5UE54cXN6MDdNOXoyVjI1NVBtaHRkbWtDSnZZN0pxWmh3Qkpidmp4ejZ3UDRjVTBCajh0OGJTamhIclMxNTFDS1BZYzZGeEQ4VWFfNVRrdEFtSER4Z3lUc3RaM2EzSDN6eFpwNXpNRXpOa3BIallBUUlldg?oc=5","date":"2026-02-26","type":"pipeline","source":"BioSpace","summary":"Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board - BioSpace","headline":"Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPV3NiMjBLRHM3ZFAzNWhpSnZheFQtSlhSeGlwYVQ5TElrSTItTllKbXpjei1ic3hJR2IxVy03TGR6TlZnaGtHS25rSjFzaUdtY3dVRTZYenVVOEE0NlVoTUpTeVE1UXh4SlJHMm94dmt6MllWZHNqQ0dQejNQd01JcC1XbmlmQVIzMTAwZHJMSmpZS081T2IzU3h6RlBYeXh6ZGlsdkxJVk5YQ0NtelFCRk1pQlA3bDQ?oc=5","date":"2026-02-13","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's After-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNODRkNVkzWFhjRXYyREZieUhIRmd5V3pmOWU1S09OWndmRGZ0dmN6WFduYmMxcUhUNnZHSlUwOXNzRDd4bHpqd0w5aHdMa1h6WmlLRm1GUVYwNnc0MWcyd2xMYWtDVWxyTXJqczlVR0lYdEJZaU0yRWVFRUR1emREM0JCSnBOUWJLVFBIZnQ2ck1sNEliN2Z0enNn?oc=5","date":"2026-01-28","type":"patent","source":"pharmatimes.com","summary":"Akari files new patent and advances second ADC targeting CEACAM5 - pharmatimes.com","headline":"Akari files new patent and advances second ADC targeting CEACAM5","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPMUJGYjhVYmo2VU9pLUFWSHNSQWg3SWx4aWZ0VFE5ZkhvUmFQQ2E2QUFvTS0xVExKMS1CQnI3U3JpU3AtalZ0LXZIa1VwY2NPR3U1ZUV4WGhpZVA2Rm5MWUxIeko0S29BcW02MU1JcmlHRlp5Wkd6LXFRcmplREJycktQeDZrZkd5aXl3MU5kX3FnMzY4dmsySHVHdUkwUjBVNzBrSWlUOHpUYnJRM3ZXWUF4bkRYLXNfYUE?oc=5","date":"2025-12-29","type":"pipeline","source":"Contract Pharma","summary":"Akari Initiates Manufacturing Activities to Support AKTX-101 Development - Contract Pharma","headline":"Akari Initiates Manufacturing Activities to Support AKTX-101 Development","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-14","type":"pipeline","source":"simplywall.st","summary":"Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m - simplywall.st","headline":"Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNUExNdTBRQWRlUGxKbTFHeHVMc1VQY1c5Z1dnSVRYRDZ3X0xWVE9RNG0tUHlsaXJ1ZDJOTXVSVG94cDYtb1EweURDUzNhRXFFTzdlSFVySktMU0lzU3d4RmxXelpleWNKWWNsRDJnVkNlMU1feTFJUDMwZnlXbjR4Uzh0X0xwUUd3MFY4bmhvanYxM3cxcUhTTw?oc=5","date":"2025-03-20","type":"pipeline","source":"citybiz","summary":"Akari Therapeutics Appoints Abizer Gaslightwala as CEO - citybiz","headline":"Akari Therapeutics Appoints Abizer Gaslightwala as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOdG5FVEtISmtiaVRZeVNMdElDcm5jVVd0S2xhNUJ3dkpCS2VpQUNMcDVxZjVFWTBDM3Y2b0tBS3BnZ0hVUURraDFrdDA5ZTdaWEN1TU1wNi1SX0ZoOEl4YzE0a2toM0lqWFA1Vy1ZNGp2UFVxQ0dmUUZFdkJqbnRnOFc4NTJHZnVHSEtKM2tZV2gzRTdJaUtKMmhfdEk?oc=5","date":"2025-03-20","type":"pipeline","source":"Yahoo Finance","summary":"Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Yahoo Finance","headline":"Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTE9LaXJIVWtnR1hlWEY2Q09VVGQ0N00xQk9iTDR1cTkyRkJMWE1PZllSNmwyd21ROHFYSkNlZWYxQjczV0FncEs1d2JoRQ?oc=5","date":"2021-02-26","type":"pipeline","source":"Benzinga","summary":"Akari Therapeutics PLC (AKTX) Stock Price, Quote, News & History - Benzinga","headline":"Akari Therapeutics PLC (AKTX) Stock Price, Quote, News & History","sentiment":"neutral"}],"patents":[{"drugName":"Coversin","drugSlug":"coversin","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0},{"drugName":"Nomacopan","drugSlug":"nomacopan","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioCryst Pharmaceuticals","Ra Pharmaceuticals","Ignyta"],"therapeuticFocus":["Rare Diseases","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":6983000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-19791000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":50562000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}